Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049005 | 1.00 | ERAP2 (0.43) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL1711305 | 1.00 | ERAP2 (0.43) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL15135507 | 0.91 | ERAP2 (0.44) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL5050396 | 0.91 | ERAP2 (0.44) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL28752252 | 0.90 | LNPEP (0.46) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL5055000 | 0.86 | ERAP2 (0.45) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL5050215 | 0.86 | ERAP2 (0.53) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL5053418 | 0.81 | MMP1 (0.43) | ERAP2LNPEPERAP1CPB2CPB1 | |
| SCHEMBL5050403 | 0.80 | CPB1 (0.54) | CPB2CPB1TLR2ECE1FOLH1 | |
| SCHEMBL10524436 | 0.79 | SLC1A2 (0.44) | LNPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3108886-A2 | CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | Syntarga B.V. (NL) | 2016-12-28 | — | — | EP | disclosed |
| US-8889868-B2 | CC-1065 analogs and their conjugates | SYNTARGA BV (NL) | 2014-11-18 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| EP-2560645-A2 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | Syntarga B.V. (NL) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133039-A2 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | SYNTARGA B.V. (NL) | 2011-10-27 | — | — | WO | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
| EP-2344478-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010062171-A2 | NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2010-06-03 | — | — | WO | disclosed |
| EP-2173739-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009017394-A1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | ERAP2 3226/4885LNPEP 1509/4885ERAP1 2042/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | ERAP2 2938/4885LNPEP 989/4885ERAP1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.